Login to Your Account



Synthetic peptide hemostat may be more convenient than plasma-derived thrombin

By Nuala Moran
Staff Writer

Monday, March 20, 2017

LONDON – Ergomed plc has started the phase IIb trial of Peprostat, the first synthetic peptide hemostat, which it said will offer faster clotting while removing concerns around plasma-derived thrombin products.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription